10 Results for "

plasma-cells

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "plasma-cells" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-139567
CAS No.: 2171019-55-7
Purity:  99.37%
Synonyms: BMS-986256
Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable TLR7/8 antagonist. Afimetoran (BMS-986256) can inhibit TLR7/8 activation of the NF-κB pathway and reverse TLR7 mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-124745
CAS No.: 1228280-29-2
Purity:  99.88%
Target:  

MAP4K Wnt Apoptosis

Research Areas:  

Cancer

KY-05009 is an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM. KY-05009 pharmacologically inhibits TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells. KY-05009 inhibits the protein expression of TNIK and transcriptional activity of Wnt target genes and induces apoptosis in cancer cells. KY-05009 exerts anti-cancer activity .
loading...
    loading...
Cat. No.: HY-N4202
CAS No.: 6659-45-6
Dihydrorotenone is an insecticide and irreversible inhibitor of mitochondrial complex I. Dihydrorotenone may induce Parkinson's disease. Dihydrorotenone induces apoptosis in human plasma cells by triggering endoplasmic reticulum stress and activating the p38 signaling pathway. The oral LD50 of dihydrorotenone in rats is approximately 2.5 g/kg. Dihydrorotenone exhibits insecticide activity and cytotoxicity to plasma cells. Dihydrorotenone can be used to establish animal models of Parkinson's disease, safety assessment of natural pesticides, and potential cancer chemoprevention studies .
loading...
    loading...
Cat. No.: HY-P990095
CAS No.: 2408319-33-3
Synonyms: REGN5459

Target:  

CD3 TNF Receptor

Research Areas:  

Cancer

Vonsetamig (REGN5459) is a human bispecific antibody targeting BCMA and CD3. Vonsetamig triggers T-cell activation, induces plasma cell depletion, and triggers low-level cytokine release. Vonsetamig can be used for the research of relapsed/refractory multiple myeloma .
loading...
    loading...
Cat. No.: HY-177632
CAS No.: 2304711-81-5
Synonyms: ION-935918; ION251
Target:  

IFNAR

Research Areas:  

Cancer

Frenlosirsen (ION-935918; ION251) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen is applicable to myeloma-related research .
loading...
    loading...
Cat. No.: HY-145425
CAS No.: 2771006-54-1
Target:  

IRE1 Apoptosis FGFR

Research Areas:  

Inflammation/Immunology

PAIR2 is a highly selective inhibitor targeting the kinase domain of human IRE1α, with a Ki value of 8.8 nM against human IRE1α. PAIR2 fully occupies the ATP-binding site of the IRE1α kinase domain, partially antagonizes the ribonuclease activity of IRE1α, specifically inhibits regulated IRE1α-dependent decay (RIDD) and its mediated substrate cleavage, while preserving the splicing function of Xbp1 mRNA. PAIR2 also promotes the differentiation of B cells into plasma cells, blocks IRE1α-induced cell apoptosis, and restores the expression of Fgfr2 mRNA in AT2 cells. PAIR2 effectively reaches a steady-state concentration in the lung tissues of Mus musculus, and serves as an important tool for investigating the function of the IRE1α signaling pathway in diseases such as pulmonary fibrosis .
loading...
    loading...
Cat. No.: HY-P990175
Anti-Mouse OX40L/CD134L Antibody (RM134L) is an anti-mouse OX40L/CD134L IgG2b monoclonal antibody. Anti-Mouse OX40L/CD134L Antibody (RM134L) reduces immune response by inhibiting the OX40/OX40L signaling pathway. Anti-Mouse OX40L/CD134L Antibody (RM134L) can inhibit plasma cell differentiation and antibody secretion. Anti-Mouse OX40L/CD134L Antibody (RM134L) can prolong the survival time of cell transplantation by inhibiting CD4 + T cells. Anti-Mouse OX40L/CD134L Antibody (RM134L) can be used for researches on inflammation and cancer such as graft versus host disease (GVHD), allergic reaction, lupus nephritis and hepatocellular carcinoma (HCC) .
loading...
    loading...
Cat. No.: HY-177632A
CAS No.: 2304711-82-6
Synonyms: ION-935918 sodium; ION251 sodium
Target:  

IFNAR

Research Areas:  

Cancer

Frenlosirsen sodium (ION-935918 sodium; ION251 sodium) is an antisense oligonucleotide and also an IRF4 inhibitor. Frenlosirsen sodium inhibits the survival of malignant plasma cells, reduces the burden of myeloma progenitor cells and prevents disease recurrence. Frenlosirsen sodium is applicable to myeloma-related research .
loading...
    loading...
Cat. No.: HY-111077
CAS No.: 933768-63-9
Target:  

JAK STAT

Research Areas:  

Inflammation/Immunology Cancer

INCB16562 is an orally active and selective inhibitor against JAK1/2 markedly selective over JAK3. INCB16562 potently inhibits interleukin-6 (IL-6)-induced phosphorylation of STAT3. Additionally, INCB16562 inhibits the proliferation and survival of myeloma cells dependent on IL-6 for growth, as well as the IL-6–induced growth of primary bone marrow-derived plasma cells. INCB16562 antagonizes the growth of myeloma xenografts in mice with antitumor activity. INCB16562 is promising for research of multiple myeloma .
loading...
    loading...
Cat. No.: HY-P991898
Synonyms: RD126

Target:  

CD19

Research Areas:  

Inflammation/Immunology

IASO-782 (RD126) is a fully human monoclonal antibody targeting human CD19. The Fc segment of IASO-782 is mutated to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) while maintaining the integrity of other Fc segment functions, such as ADCP. IASO-782 effectively eliminates CD19+ B cells, plasmablasts, and some plasma cells, thereby reducing or completely eliminating autoreactive antibodies produced by these cells. IASO-782 can be used for the study of immune thrombocytopenic purpura (ITP), warm autoimmune hemolytic anemia (wAIHA) and systemic lupus erythematosus (SLE).
loading...
    loading...